Predicting the Actual Incidence of Preeclampsia via Screening in the Second Trimester of Pregnancy in Women Referring to the Perinatology Clinic of Sabzevar University of Medical Sciences between 2021 And 2022

Document Type : Original Article

Authors

1 Department of Obstetrics & Gynecology, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.

2 Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.

3 Department of Anesthesiology, School of Medicine, Sabzevar University of Medical Sciences

4 Department of Gynecology and Obstetrics, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.

5 Master of Midwifery, teaching assistant of Sabzevar University of Medical Sciences

10.22038/ijogi.2024.75271.5874

Abstract

Introduction: Preeclampsia occurs as a result of poor perfusion of the placental vessels, which is caused by insufficient regeneration of the spiral arteries of the maternal uterus. Early diagnosis and prediction of preeclampsia may prevent fetal and maternal complications. Materials and methods: This cross-sectional study was conducted between 1400 and 1401 on 150 patients with high risk of preeclampsia in the screening of the second trimester of pregnancy. Pre-eclampsia was diagnosed with hospitalization documentation. Analysis, descriptive tests and derived indices of accuracy, performance characteristic diagram (AUC) were used. Results: Out of 150 people who were identified as high-risk for preeclampsia based on screening in the second trimester of pregnancy, 12 people (8%) were diagnosed with preeclampsia. The accuracy of AFP was 0.45, inhibin A was 0.43, beteHCG was 0.27 and UE3 was 0.57 for predicting preeclampsia. With 95% confidence, the UE3 level between 0.42 and 0.73 had the best diagnostic value for preeclampsia. The highest sensitivity and specificity of UE3 for predicting preeclampsia was 66% and 49%, respectively, for MOM point 0.74. Discussion and conclusion: The findings showed that the reduction of non-conjugated estriol can be used as a biomarker in the prediction of preeclampsia. The high risk of screening in the second trimester of pregnancy alone cannot predict the risk of preeclampsia. However, it is recommended to conduct multicenter studies including different populations to determine its utility as a routine screening test.

Keywords

Main Subjects